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OBJECTIVE: The LIFE Study demonstrated a signiﬁcant
reduction in cardiovascular morbidity and mortality in
hypertensive patients with ECG left ventricular hypertro-
phy treated with losartan (versus treatment with atenolol)
over a mean period of 4.8 years. This reduction was
essentially related to a signiﬁcant 25% decrease (p =
0.001) in the risk of fatal and non-fatal stroke. The objec-
tive of this study was to compare the treatment costs
relating to each therapeutic strategy throughout the dura-
tion of the LIFE Study. METHODS: Data on efﬁcacy and
resources consumed were extracted from the published
results of the LIFE study. A cost minimization study was
carried out and the costs were calculated from the point
of view of the French Health care system. The total esti-
mated direct costs included those relating to the medici-
nal product and management of the cardiovascular events
(myocardial infarction, angina pectoris, heart failure,
stroke and revascularization). The medicinal products
were valued on the basis of the purchasing price (retail
price inc. VAT), and hospitalization costs were estimated
on the basis of PMSI data and the national cost scale.
Indirect costs were not considered. RESULTS: Over the
4.8 years, the mean cost of losartan per patient ranged
from €1132 (lower bound) to €1199 (upper bound). The
mean cost of atenolol per patient was €366. The mean
cost of the cardiovascular events were respectively €1969
and €2261 for losartan and atenolol groups. Therefore,
the total mean cost per patient ranged from €3101 to
€3169 for the losartan group and was estimated €2627
for the atenolol group. CONCLUSION: The annual
incremental cost for each patient treated with losartan
ranged from €99 to €113. This additional cost is associ-
ated with a signiﬁcant reduction in cardiovascular mor-
bidity and mortality (especially stroke).
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OBJECTIVES: Rosuvastatin (Crestor®) is a new statin
with proven efﬁcacy for reducing plasma low-density
lipoprotein cholesterol (LDL-C) levels. A model has been
developed to estimate the budget impact and incremental
cost-effectiveness of rosuvastatin compared with other
statins for reducing LDL-C levels and treating patients to
goal. METHODS: The model considered the treatment
of an adult population with hypercholesterolaemia over
a 1-year period from the perspective of the UK primary
Health care provider. The clinical beneﬁt was a simulated
estimate of the proportion of the population attaining 
the European Atherosclerosis Society (EAS) guideline 
goal LDL-C plasma level (<3mmol/L). The model com-
pared the cost of statin treatment using current prescrib-
ing patterns with a scenario in which 30% of patients
currently receiving statins are switched to rosuvastatin.
Patients are switched from existing products according 
to market share. Sensitivity analyses varied the potential
prescribing share of rosuvastatin. RESULTS: Following
rosuvastatin introduction, the anticipated cost saving 
for a population of 1,000 patients would be £8,052
(€12,849) per year, with an additional 103 patients reach-
ing the EAS goal LDL-C level. Assuming a ﬁxed budget,
the introduction of rosuvastatin would allow an addi-
tional 30 patients to be treated with rosuvastatin, with a
total 132 extra patients achieving the goal. The analysis
showed that rosuvastatin is cost-effective compared 
with atorvastatin, pravastatin and simvastatin. Sensitivity
analyses showed that the results were robust to changes
in the prescribing share of rosuvastatin. CONCLUSION:
The introduction of rosuvastatin into primary care pre-
scribing should enable more patients to be treated with a
statin than is currently possible, and more patients would
reach EAS goal LDL-C levels. Compared with other cur-
rently available statins, prescribing rosuvastatin would
allow resources to be used more efﬁciently. The model can
be adapted for any European country to determine the
cost-effectiveness and potential budget impact of a new
statin.
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OBJECTIVE: Evidence-based medicine guidelines based
on venographic end points recommend extended venous
thromboembolism (VTE) prophylaxis with low-
molecular-weight heparin (LMWH) in patients having
elective hip surgery. The aim of the study was to estimate
the expected cost-effectiveness of such prophylaxis with
enoxaparin administered for 21 days postdischarge 
vs. using enoxaparin for hospital admission only.
METHODS: Decision analysis model was developed to
